228 results on '"Kalil, Andre C."'
Search Results
2. Remdesivir is associated with reduced mortality in patients hospitalized for COVID-19 not requiring supplemental oxygen
3. Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study
4. True DisCoVeRy of COVID-19 Disease Burden Versus Speculated Antiviral Cardiovascular Risk Requires a Control Group
5. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence
6. Universal Risk Factors for Mortality in Bloodstream Infections (UNIFORM): a systematic review and Delphi survey
7. A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
8. Improving Sepsis Outcomes in the Era of Pay-for-Performance and Electronic Quality Measures: A Joint IDSA/ACEP/PIDS/SHEA/SHM/SIDP Position Paper
9. Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU
10. Executive Summary: Guidelines for Evaluating New Fever in Adult Patients in the ICU
11. Remdesivir Is Associated With Reduced Mortality in COVID-19 Patients Requiring Supplemental Oxygen Including Invasive Mechanical Ventilation Across SARS-CoV-2 Variants
12. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for Coronavirus Disease 2019 Across Variant Waves: Findings From Routine Clinical Practice
13. Which trial do we need? One or two antimicrobials with anti-pseudomonal activity for the empirical treatment of Ventilator-associated pneumonia due to Gram-negative bacteria
14. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case
15. THE IMPACT OF THE COVID-19 PANDEMIC ON NON-COVID-19 COMMUNITY-ACQUIRED PNEUMONIA, A RETROSPECTIVE COHORT STUDY
16. Baricitinib treatment of COVID-19 is associated with a reduction of secondary infections
17. Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia
18. Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19*
19. Remdesivir saves lives. Were 3 years needed to learn that?
20. Déjà vu all over again? Monkeypox and the urgent need for randomised controlled trials
21. Omicron variant: assessing the duration of viral shedding and its implications
22. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
23. Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?
24. Preparing the Intensive Care Unit for a Lethal Viral Respiratory Pandemic
25. Immunomodulators in Mechanically Ventilated Patients With COVID-19: Lessons Learned From Underpowered Trials*
26. Of Granularity and Generality: ICU-Onset Bloodstream Infections and the Need for Antimicrobial Stewardship and Infection Prevention*
27. Adjunctive Rifampin Following Debridement and Implant Retention for Staphylococcal Prosthetic Joint Infection: Is it Effective if not Combined With a Fluoroquinolone?
28. Less Is More: A 7-Day Course of Antibiotics Is the Evidence-Based Treatment forPseudomonas aeruginosaVentilator-Associated Pneumonia
29. The Potential for Increasing Risk of Consent Refusal in COVID-19 Trials: Considering Underlying Reasons and Responses
30. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
31. Molecular Targets for Therapy
32. Lower Respiratory Tract Coinfection in the ICU: Prevalence and Clinical Significance of Coinfection Detected via Microbiological Analysis of Bronchoalveolar Lavage Fluid With a Comparison of Invasive Methodologies
33. From Syphilis to Sepsis: Pilot Studies and the Importance of Staying Grounded*
34. Prediction models in CMI
35. The Puzzles of Ventilator-Associated Pneumonia and COVID-19: Absolute Knowns and Relative Unknowns*
36. Molnupiravir: Is It Time to Move In or Move Out?
37. Mortality in solid organ transplant recipients hospitalized for COVID-19
38. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial
39. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
40. Repurposed drugs for COVID-19: threshold and proof requirements for trials
41. Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?*
42. Risk of COVID‐19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At‐Risk Individuals
43. Sepsis and Septic Shock
44. Survival Outcome of Sepsis in Recipients of Solid Organ Transplant
45. Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
46. Editorial: COVID-19: A New Severe Infection
47. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort
48. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
49. Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment*
50. Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.